Schechter Investment Advisors LLC Sells 5,755 Shares of Koninklijke Philips (NYSE:PHG)

Schechter Investment Advisors LLC cut its position in shares of Koninklijke Philips (NYSE:PHG) by 9.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 54,701 shares of the technology company’s stock after selling 5,755 shares during the period. Schechter Investment Advisors LLC’s holdings in Koninklijke Philips were worth $1,276,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. increased its holdings in Koninklijke Philips by 7.4% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 13,619 shares of the technology company’s stock worth $318,000 after purchasing an additional 940 shares during the period. Raymond James & Associates lifted its position in Koninklijke Philips by 1.0% during the 4th quarter. Raymond James & Associates now owns 450,177 shares of the technology company’s stock worth $10,503,000 after acquiring an additional 4,507 shares during the period. Contravisory Investment Management Inc. acquired a new stake in Koninklijke Philips during the 4th quarter worth about $200,000. Legacy Wealth Asset Management LLC raised its stake in shares of Koninklijke Philips by 13.0% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 54,391 shares of the technology company’s stock valued at $1,269,000 after buying an additional 6,273 shares during the last quarter. Finally, Sanders Morris Harris LLC purchased a new position in shares of Koninklijke Philips during the 4th quarter valued at about $213,000. 13.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PHG has been the subject of several recent analyst reports. StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. BNP Paribas cut Koninklijke Philips from an “outperform” rating to an “underperform” rating in a report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Koninklijke Philips Stock Up 1.4 %

PHG stock opened at $20.32 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20. The business has a 50 day simple moving average of $21.00 and a 200-day simple moving average of $20.93. Koninklijke Philips has a 1 year low of $16.18 and a 1 year high of $24.27.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.47 billion. Sell-side analysts anticipate that Koninklijke Philips will post 1.52 EPS for the current year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.